Scopus: 0 citations, Google Scholar: citations,
Alzheimer's disease in Down syndrome : An overlooked population for prevention trials
Strydom, André (South London and Maudsley NHS Foundation Trust)
Coppus, Antonia (Department of Primary and Community Care, Radboud University Medical Center, Nijmegen)
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau)
Danek, Adrian (Department of Neurology, Ludwig-Maximilians-Universität München)
Fortea, Juan (Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down)
Hardy, John (Reta Lila Weston Institute, Institute of Neurology, University College London)
Levin, Johannes (German Center for Neurodegenerative Diseases (DZNE) site Munich)
Nuebling, Georg (Department of Neurology, Ludwig-Maximilians-Universität München)
Rebillat, Anne-Sophie (Institut Jérôme Lejeune)
Ritchie, Craig (Centre for Clinical Brain Sciences. University of Edinburgh)
van Duijn, Cornelia (Department of Epidemiology, Erasmus Medical Centre, Rotterdam)
Zaman, Shahid (Cambridgeshire & Peterborough NHS Foundation Trust (CBFT), Fulbourn Hospital)
Zetterberg, Henrik (Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital)
Universitat Autònoma de Barcelona

Date: 2018
Abstract: The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Individuals with DS have a lifetime risk for dementia in excess of 90%, and DS is now acknowledged to be a genetic form of AD similar to rare autosomal-dominant causes. Just as DS put the spotlight on amyloid precursor protein mutations, it is also likely to inform us of the impact of manipulating the amyloid pathway on treatment outcomes in AD. Ironically, however, individuals with DS are usually excluded from AD trials. This review will discuss primary and secondary prevention trials for AD in DS and the potential barriers and solutions to such trials and describe the Europe-wide Horizon21 Consortium to establish a DS-AD prevention clinical trials network.
Note: Número d'acord de subvenció WT/098330-Z-12-Z
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Alzheimer's disease ; Down syndrome ; Trisomy 21 ; Randomized controlled trials ; Prevention ; Dementia ; APP ; Amyloid ; Biomarkers
Published in: Alzheimer's & Dementia : Translational Research & Clinical Interventions, Vol. 4 (december 2018) , p. 703-713, ISSN 2352-8737

PMID: 30581976
DOI: 10.1016/j.trci.2018.10.006


11 p, 1.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació Biomèdica Sant Pau
Articles > Research articles
Articles > Published articles

 Record created 2019-05-06, last modified 2019-06-03



   Favorit i Compartir